AUB ScholarWorks

Clinical trial: A randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia

Show simple item record

dc.contributor.author Hashash J.G.
dc.contributor.author Abdul-Baki H.
dc.contributor.author Azar C.
dc.contributor.author Elhajj I.I.
dc.contributor.author El Zahabi L.
dc.contributor.author Chaar H.F.
dc.contributor.author Sharara A.I.
dc.contributor.editor
dc.date Jun-2008
dc.date.accessioned 2017-10-05T15:37:29Z
dc.date.available 2017-10-05T15:37:29Z
dc.date.issued 2008
dc.identifier 10.1111/j.1365-2036.2008.03677.x
dc.identifier.isbn
dc.identifier.issn 02692813
dc.identifier.uri http://hdl.handle.net/10938/15742
dc.description.abstract Background: Functional dyspepsia is a prevalent condition associated with diminished quality of life (QoL) and high economic burden. Aim: To study the efficacy of a combination of flupenthixol and melitracen (F + M) with anxiolytic and antidepressant properties in functional dyspepsia using a randomized controlled cross-over design. Methods: Patients met the Rome III criteria for functional dyspepsia and a validated questionnaire was used to exclude those with anxiety or depression. Moreover, patients had to have failed a trial of acid-suppressive therapy and Helicobacter pylori eradication when positive. End points included subjective global symptom relief and QoL assessed by the Nepean Dyspepsia Index (NDI). Results: Twenty-five patients (14 females, 11 males; mean age = 34.3 ± 9.9 years) were enrolled and 24 completed the 8-week study. There was a significant improvement in subjective global symptom relief with F + M vs. placebo (ITT: 73.9percent vs. 26.1percent, P = 0.001) and a significant drop in the NDI score vs. placebo (ITT: -9.0 ± 11.9 vs. -2.4 ± 8.9, P = 0.03). No difference was noted whether the initial treatment was F + M or placebo. No significant side effects were noted. Conclusions: A combination of F and M is safe and effective in the short-term treatment of functional dyspepsia. F + M is associated with significant improvement in QoL independent of the presence of anxiety or depression. © 2008 The Authors.
dc.format.extent
dc.format.extent Pages: (1148-1155)
dc.language English
dc.publisher MALDEN
dc.relation.ispartof Publication Name: Alimentary Pharmacology and Therapeutics; Publication Year: 2008; Volume: 27; no. 11; Pages: (1148-1155);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Clinical trial: A randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia
dc.type Article
dc.contributor.affiliation Hashash, J.G., Division of Gastroenterology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Abdul-Baki, H., Division of Gastroenterology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Azar, C., Division of Gastroenterology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Elhajj, I.I., Division of Gastroenterology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation El Zahabi, L., Division of Gastroenterology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Chaar, H.F., School of Pharmacy, Lebanese American University, Byblos, Lebanon
dc.contributor.affiliation Sharara, A.I., Division of Gastroenterology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon, Division of Gastroenterology, American University of Beirut Medical Center, PO Box 11-0236, Riad El Solh 110 72020, Beirut, Lebanon
dc.contributor.authorAddress Sharara, A. I.; Division of Gastroenterology, American University of Beirut Medical Center, PO Box 11-0236, Riad El Solh 110 72020, Beirut, Lebanon; email: as08@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Gastroenterology and Hepatology;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision Gastroenterology and Hepatology
dc.contributor.authorEmail as08@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Hashash, JG
dc.contributor.authorInitials Abdul-Baki, H
dc.contributor.authorInitials Azar, C
dc.contributor.authorInitials Elhajj, II
dc.contributor.authorInitials El Zahabi, L
dc.contributor.authorInitials Chaar, HF
dc.contributor.authorInitials Sharara, AI
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Sharara, AI (reprint author), Amer Univ Beirut, Div Gastroenterol, Dept Internal Med, Med Ctr, POB 11-0236,Riad Solh 110, Beirut 72020, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Bin Yaacob H, 1985, Dent J Malays, V8, P37; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016-S0022-3999(01)00296-3; Blum AL, 1998, NEW ENGL J MED, V339, P1875, DOI 10.1056-NEJM199812243392602; Bolling-Sternevald E, 2002, SCAND J GASTROENTERO, V37, P1395, DOI 10.1080-003655202762671260; Bouin M, 2002, GASTROENTEROLOGY, V122, P1771, DOI 10.1053-gast.2002.33601; Camilleri M, 2005, CLIN GASTROENTEROL H, V3, P543, DOI 10.1053-S1542-3565(05)00153-9; DOBRILLA G, 1989, J CLIN GASTROENTEROL, V11, P169, DOI 10.1097-00004836-198904000-00011; FARUP PG, 1991, SCAND J GASTROENTERO, V26, P1209, DOI 10.3109-00365529108998616; Gerson LB, 2005, DIGEST LIVER DIS, V37, P87, DOI 10.1016-j.dld.2004.09.021; Gisbert JP, 2002, MED CLIN-BARCELONA, V118, P405; Goves J, 1998, ALIMENT PHARM THERAP, V12, P147; HAMILTON BA, 1989, PHARMATHERAPEUTICA, V5, P292; HEILPORN A, 1978, PARAPLEGIA, V15, P368; Hertling I, 2003, NEUROPSYCHOBIOLOGY, V47, P37, DOI 10.1159-000068874; Hiyama T, 2007, J GASTROEN HEPATOL, V22, P304, DOI 10.1111-j.1440-1746.2006.04493.x; Holtmann G, 2003, ALIMENT PHARM THERAP, V18, P1099, DOI 10.1046-j.1365-2036.2003.01767.x; HOLTMANN G, 1993, DRUGS, V45, P918, DOI 10.2165-00003495-199345060-00005; HOSTMAELINGEN HJ, 1989, CURR MED RES OPIN, V11, P593; Jones RH, 1997, ALIMENT PHARM THERAP, V11, P541, DOI 10.1046-j.1365-2036.1997.00179.x; Kato M, 2005, ALIMENT PHARM THERAP, V21, P27, DOI 10.1111-j.1365-2036.2005.02470.x; KEOHANE J, 2006, WORLD J GASTROENTERO, V7, P2672; Khalil MS, 2006, SAUDI MED J, V27, P1554; Koelz HR, 2003, GUT, V52, P40, DOI 10.1136-gut.52.1.40; Kuhn KU, 2004, FORTSCHR NEUROL PSYC, V72, P397, DOI 10.1055-s-2004-818386; KUTCHER S, 1995, J PSYCHIATR NEUROSCI, V20, P113; Laine L, 2001, ANN INTERN MED, V134, P361; LANCE P, 1986, J CLIN GASTROENTEROL, V8, P414, DOI 10.1097-00004836-198608000-00006; Longstreth GF, 2006, NEW ENGL J MED, V354, P791, DOI 10.1056-NEJMp058326; Mahadeva S, 2006, WORLD J GASTROENTERO, V12, P2661; MAJID I, 1986, PHARMATHERAPEUTICA, V4, P405; Mason I, 1998, ALIMENT PHARM THERAP, V12, P263; Mazzoleni LE, 2006, DIGEST DIS SCI, V51, P89, DOI 10.1007-s10620-006-3090-6; McColl K, 1998, NEW ENGL J MED, V339, P1869, DOI 10.1056-NEJM199812243392601; Meineche-Schmidt V, 1999, SCAND J GASTROENTERO, V34, P566; Mertz H, 1998, GUT, V42, P814; Mertz H, 1998, AM J GASTROENTEROL, V93, P160; MERTZ H, 1995, GASTROENTEROLOGY, V109, P40, DOI 10.1016-0016-5085(95)90267-8; Miwa H, 2000, ALIMENT PHARM THERAP, V14, P317; Moayyedi P, 2004, GASTROENTEROLOGY, V127, P1329, DOI 10.1053-j.gastro.2004.08.026; Moayyedi P, 2001, COCHRANE DB SYST REV, V1; Moayyedi P, 2003, AM J GASTROENTEROL, V98, P2621, DOI 10.1016-j.amjgastroenterol.2003.07.003; Montazeri Ali, 2003, Health Qual Life Outcomes, V1, P14, DOI 10.1186-1477-7525-1-14; O'Mahony S, 2006, WORLD J GASTROENTERO, V12, P2681; Oshima T, 2006, J GASTROENTEROL, V41, P718, DOI 10.1007-s00535-006-1865-3; Pallant JF, 2007, BRIT J CLIN PSYCHOL, V46, P1, DOI 10.1348-014466506X96931; Peura DA, 2007, DIGEST DIS SCI, V52, P983, DOI 10.1007-s10620-006-9156-7; Peura DA, 2004, AM J MED, V116, P740, DOI 10.1016-j.amjmed.2004.01.008; Redstone HA, 2001, ALIMENT PHARM THERAP, V15, P1291, DOI 10.1046-j.1365-2036.2001.01044.x; Salet GAM, 1998, GUT, V42, P823; Samsom M, 1999, GASTROENTEROLOGY, V116, P515, DOI 10.1016-S0016-5085(99)70171-X; SAUNDERS JHB, 1986, BRIT MED J, V292, P665; Seno H, 2005, ALIMENT PHARM THERAP, V21, P32, DOI 10.1111-j.1365-2036.2005.02471.x; Tack J, 2003, ALIMENT PHARM THERAP, V17, P603, DOI 10.1046-j.0269-2813.2003.01469.x; Tack J, 2005, J CLIN GASTROENTEROL, V39, pS211, DOI 10.1097-01.mcg.0000156109.97999.d1; Tack J, 2004, GASTROENTEROLOGY, V127, P1058, DOI 10.1053-j.gastro.2004.07.005; Tack J, 2006, GASTROENTEROLOGY, V130, P1466, DOI 10.1053-j.gastro.2005.11.059; Talley NJ, 2002, GUT, V50, P36; Talley NJ, 2006, ALIMENT PHARM THERAP, V23, P923, DOI 10.1111-j.1365-2036.2006.02845.x; Talley NJ, 2001, ALIMENT PHARM THERAP, V15, P207, DOI 10.1046-j.1365-2036.2001.00900.x; Talley NJ, 1999, NEW ENGL J MED, V341, P1106, DOI 10.1056-NEJM199910073411502; Talley NJ, 1999, ALIMENT PHARM THERAP, V13, P1135; TALLEY NJ, 1986, GASTROENTEROLOGY, V91, P149; Talley NJ, 2001, ALIMENT PHARM THERAP, V15, P525, DOI 10.1046-j.1365-2036.2001.00941.x; Talley Nicholas J, 2005, Gastroenterology, V129, P1756, DOI 10.1053-j.gastro.2005.09.020; Talley NJ, 1998, ALIMENT PHARM THERAP, V12, P1055; Vakil N, 2001, DIGEST DIS, V19, P240, DOI 10.1159-000050686; Van Moffaert M, 1983, Acta Psychiatr Belg, V83, P525; van Zanten SJOV, 2005, AM J GASTROENTEROL, V100, P1477, DOI 10.1111-j.1572-0241.2005.40280.x; van Zanten SJOV, 2001, AM J GASTROENTEROL, V96, P689; Wang WH, 2007, CLIN GASTROENTEROL H, V5, P178, DOI 10.1016-j.cgh.2006.09.012; Wong WM, 2002, GUT, V51, P502, DOI 10.1136-gut.51.4.502; YOUNG JPR, 1976, BRIT MED J, V1, P1116; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111-j.1600-0447.1983.tb09716.x
dc.description.citedCount 18
dc.description.citedTotWOSCount 18
dc.description.citedWOSCount 11
dc.format.extentCount 8
dc.identifier.articleNo
dc.identifier.coden APTHE
dc.identifier.pubmedID 18331614
dc.identifier.scopusID 42949173367
dc.identifier.url
dc.publisher.address COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Aliment. Pharmacol. Ther.
dc.relation.ispartOfIssue 11
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Alimentary Pharmacology and Therapeutics
dc.relation.ispartofPubTitleAbbr Aliment. Pharmacol. Ther.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 27
dc.source.ID WOS:000255463200016
dc.type.publication Journal
dc.subject.otherAuthKeyword
dc.subject.otherChemCAS flupentixol, 2413-38-9, 2709-56-0
dc.subject.otherChemCAS melitracen, 5118-29-6
dc.subject.otherChemCAS Anthracenes
dc.subject.otherChemCAS Antipsychotic Agents
dc.subject.otherChemCAS Flupenthixol, 2709-56-0
dc.subject.otherChemCAS melitracene, 5118-29-6
dc.subject.otherIndex flupentixol
dc.subject.otherIndex melitracen
dc.subject.otherIndex placebo
dc.subject.otherIndex adult
dc.subject.otherIndex article
dc.subject.otherIndex clinical trial
dc.subject.otherIndex controlled clinical trial
dc.subject.otherIndex controlled study
dc.subject.otherIndex crossover procedure
dc.subject.otherIndex diarrhea
dc.subject.otherIndex drug effect
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug safety
dc.subject.otherIndex drug treatment failure
dc.subject.otherIndex dyspepsia
dc.subject.otherIndex female
dc.subject.otherIndex generalized discomfort
dc.subject.otherIndex heartburn
dc.subject.otherIndex human
dc.subject.otherIndex insomnia
dc.subject.otherIndex male
dc.subject.otherIndex nepean dyspepsia index
dc.subject.otherIndex outcome assessment
dc.subject.otherIndex physical disease
dc.subject.otherIndex priority journal
dc.subject.otherIndex quality of life
dc.subject.otherIndex questionnaire
dc.subject.otherIndex randomized controlled trial
dc.subject.otherIndex symptom
dc.subject.otherIndex United States
dc.subject.otherIndex Adult
dc.subject.otherIndex Anthracenes
dc.subject.otherIndex Antipsychotic Agents
dc.subject.otherIndex Cross-Over Studies
dc.subject.otherIndex Drug Therapy, Combination
dc.subject.otherIndex Dyspepsia
dc.subject.otherIndex Female
dc.subject.otherIndex Flupenthixol
dc.subject.otherIndex Humans
dc.subject.otherIndex Male
dc.subject.otherIndex Statistics as Topic
dc.subject.otherKeywordPlus HELICOBACTER-PYLORI INFECTION
dc.subject.otherKeywordPlus QUALITY-OF-LIFE
dc.subject.otherKeywordPlus PLACEBO-CONTROLLED TRIALS
dc.subject.otherKeywordPlus PROTON-PUMP INHIBITORS
dc.subject.otherKeywordPlus IRRITABLE-BOWEL-SYNDROME
dc.subject.otherKeywordPlus ACID-RELATED DYSPEPSIA
dc.subject.otherKeywordPlus NONULCER DYSPEPSIA
dc.subject.otherKeywordPlus DOUBLE-BLIND
dc.subject.otherKeywordPlus GENERAL-PRACTICE
dc.subject.otherKeywordPlus DEPRESSION SCALE
dc.subject.otherWOS Gastroenterology and Hepatology
dc.subject.otherWOS Pharmacology and Pharmacy


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account